Study of guselkumab plus JAK inhibitors for tough-to-treat IBD
Part of Digestive system, Immune system & allergy clinical trials.
This trial tests a combination of two medications—guselkumab and a JAK inhibitor—for people with inflammatory bowel disease that hasn't responded to other treatments. The goal is to see if this combination is safe and effective for patients with hard-to-control Crohn's disease or ulcerative colitis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 80 years old and have been diagnosed with inflammatory bowel disease (IBD).
- Your IBD is considered difficult to treat, meaning you have tried and failed at least two different types of biologic medications, or you have Crohn's disease that came back after two or more bowel surgeries, or you have complex anal fistulas that didn't improve with other treatments.
- Your disease is currently moderate to severe, with specific scores from your doctor showing active inflammation.
- You do not have an active infection, abscess, cancer, serious heart or lung problems, or a history of blood clots.
- You have not had a bad reaction to JAK inhibitors or IL-23 inhibitors (like guselkumab) in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether guselkumab, a different biologic medicine, can help people with Crohn's disease who have already tried ustekinumab but it didn't work well or caused side effects. It aims to see if switching to guselkumab is safe and effective.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This trial tests whether guselkumab, a newer biologic medication, can treat people who have both inflammatory bowel disease (Crohn's disease or ulcerative colitis) and spondyloarthritis (joint inflammation and pain). Researchers want to see if this one drug can help both conditions at the same time.
This study tests whether guselkumab, a newer biologic medication, can better control active Crohn's disease symptoms and inflammation. You'll receive the medication and be monitored closely to see how well it works for you.
This study looks at how well guselkumab works in real life for people with moderate-to-severe Crohn's disease or ulcerative colitis. It tracks patients in the UK who start guselkumab as part of their normal care.
This trial tests whether switching from the drug ustekinumab to another drug called guselkumab can help people with active inflammatory bowel disease (IBD) who didn't get enough benefit from ustekinumab. It focuses on people with Crohn's disease or ulcerative colitis who still have signs of inflammation in their gut.
Hear when a new Inflamatory Bowel Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.